CA3108773A1 - 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases - Google Patents

2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases Download PDF

Info

Publication number
CA3108773A1
CA3108773A1 CA3108773A CA3108773A CA3108773A1 CA 3108773 A1 CA3108773 A1 CA 3108773A1 CA 3108773 A CA3108773 A CA 3108773A CA 3108773 A CA3108773 A CA 3108773A CA 3108773 A1 CA3108773 A1 CA 3108773A1
Authority
CA
Canada
Prior art keywords
alkyl
chosen
alkoxy
amino
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3108773A
Other languages
English (en)
French (fr)
Inventor
Samuel D. BANISTER
Edgar Engleman
Khoa D. Nguyen
Mark Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CA3108773A1 publication Critical patent/CA3108773A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65068—Five-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3108773A 2018-08-06 2019-08-06 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases Pending CA3108773A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862714962P 2018-08-06 2018-08-06
US62/714,962 2018-08-06
PCT/US2019/045229 WO2020033359A1 (en) 2018-08-06 2019-08-06 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases

Publications (1)

Publication Number Publication Date
CA3108773A1 true CA3108773A1 (en) 2020-02-13

Family

ID=69413327

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3108773A Pending CA3108773A1 (en) 2018-08-06 2019-08-06 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases

Country Status (13)

Country Link
US (3) US12195432B2 (cg-RX-API-DMAC7.html)
EP (1) EP3833344A4 (cg-RX-API-DMAC7.html)
JP (2) JP7422737B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210068399A (cg-RX-API-DMAC7.html)
CN (2) CN119033775A (cg-RX-API-DMAC7.html)
AU (1) AU2019319745B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021002165A2 (cg-RX-API-DMAC7.html)
CA (1) CA3108773A1 (cg-RX-API-DMAC7.html)
IL (3) IL280664B2 (cg-RX-API-DMAC7.html)
MX (2) MX2021001456A (cg-RX-API-DMAC7.html)
SG (1) SG11202101285YA (cg-RX-API-DMAC7.html)
TW (1) TWI904076B (cg-RX-API-DMAC7.html)
WO (1) WO2020033359A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2830447T3 (es) 2015-12-15 2021-06-03 Univ Leland Stanford Junior Método para la prevención y/o el tratamiento del deterioro cognitivo asociado al envejecimiento y la neuroinflamación
BR112021002165A2 (pt) 2018-08-06 2021-05-04 The Board Of Trustees Of The Leland Stanford Junior University composto, composição farmacêutica, e, métodos para tratar uma doença neurodegenerativa e deficiência cognitiva associada ao envelhecimento e neuroinflamação
EP4118435A1 (en) * 2020-03-13 2023-01-18 Biorchestra Co., Ltd. Diagnostic methods using pgc-1? expression
CN112933232A (zh) * 2021-02-02 2021-06-11 袁玉佳 PGC-1α激活TFEB介导的自噬在制备治疗急性肾损伤的药物中的应用
CN118541152A (zh) * 2021-11-02 2024-08-23 特朗奎斯治疗股份有限公司 具有循环髓样细胞炎性表型的受试者的选择和治疗
US20250262189A1 (en) * 2022-04-22 2025-08-21 Rdiscovery, LLC Treatment of diseases associated with reductive stress
CN120752039A (zh) * 2022-11-18 2025-10-03 五条聪 Zln-005和相关化合物的用途
US20260199293A1 (en) * 2022-12-02 2026-07-16 Tranquis Therapeutics, Inc. 2-Arylbenzimidazole Compounds for the Treatment of Hemoglobinopathies

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL275435A (cg-RX-API-DMAC7.html) * 1961-03-01
FR1569337A (cg-RX-API-DMAC7.html) * 1968-06-18 1969-05-30
US4038396A (en) 1975-02-24 1977-07-26 Merck & Co., Inc. Anti-inflammatory oxazole[4,5-b]pyridines
GB1584296A (en) * 1976-12-07 1981-02-11 Kanebo Ltd 2-substituted benzimidazole compounds
NZ234564A (en) 1986-11-21 1991-04-26 Haessle Ab 1-substituted benzimidazoles and pharmaceutical compositions
DE3830060A1 (de) 1988-09-03 1990-03-15 Boehringer Mannheim Gmbh 2-phenylbenzimidazole - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US5552426A (en) 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide
JPH09169729A (ja) * 1995-12-19 1997-06-30 Green Cross Corp:The 非ペプチド型インターロイキン8拮抗剤
CA2258728C (en) * 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
JP2000143635A (ja) * 1998-06-10 2000-05-26 Takeda Chem Ind Ltd 血管新生阻害剤
JP2000095767A (ja) * 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
TR200101239T2 (tr) * 1998-11-03 2001-11-21 Basf Aktiengesellschaft İkameli-2-fenilbenzimidazoller, üretimleri ve kullanımları
JP2004515496A (ja) * 2000-12-07 2004-05-27 アストラゼネカ・アクチエボラーグ ベンズイミダゾール治療剤
DE10134775A1 (de) * 2001-07-06 2003-01-30 Schering Ag 1-Alkyl-2.aryl-benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
SE0301371D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab New Compounds
WO2005112913A1 (en) 2004-05-20 2005-12-01 The Scripps Research Institute Transthyretin stabilization
BRPI0512239A (pt) 2004-06-17 2008-02-19 Wyeth Corp processos para preparação de antagonistas de receptores de hormÈnios liberadores de gonatropina
WO2006122546A1 (de) 2005-05-18 2006-11-23 Forschungsverbund Berlin E.V. Nicht-peptidische inhibitoren der akap-pka-wechselwirkung
CA2616512A1 (en) 2005-07-28 2007-02-08 Intervet International B.V. Novel benzimidazole (thio) carbamates with antiparasitic activity and the synthesis thereof
US7345178B2 (en) 2005-08-04 2008-03-18 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
WO2008059026A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
GB0807103D0 (en) 2008-04-18 2008-05-21 Univ Bradford The Compounds
US8835648B2 (en) * 2009-06-11 2014-09-16 Siena Biotech S.P.A. Hedgehog pathway antagonists and therapeutic applications thereof
WO2011047129A1 (en) 2009-10-15 2011-04-21 Southern Research Institute Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
MX2012005248A (es) * 2009-11-06 2012-06-14 Univ Vanderbilt Aril- y heteroaril-sulfonas como potenciadores alostericos de mglur4, composiciones y metodos de tratamiento de la disfuncion neurologica.
GB201009656D0 (en) * 2010-06-09 2010-07-21 Univ St Andrews Carboxylation catalysts
JP5083393B2 (ja) 2010-09-16 2012-11-28 カシオ計算機株式会社 画像表示装置及びプログラム
EP2651405A2 (en) 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
WO2012118935A1 (en) 2011-03-03 2012-09-07 Proteotech Inc Compounds for the treatment of neurodegenerative diseases
CN104662018B (zh) 2012-04-20 2017-10-24 阿迪维纳斯治疗有限公司 取代的杂双环化合物、组合物及其医疗应用
WO2014037340A1 (de) * 2012-09-05 2014-03-13 Bayer Cropscience Ag Verwendung substituierter 2-amidobenzimidazole, 2-amidobenzoxazole und 2-amidobenzothiazole oder deren salze als wirkstoffe gegen abiotischen pflanzenstress
KR101435496B1 (ko) 2012-10-22 2014-08-28 한국과학기술연구원 미토콘드리아 기능 조절제로서의 벤즈이미다졸 유도체
GB201302927D0 (en) * 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
CN103113307B (zh) * 2013-02-27 2015-08-05 南京大学 苯并咪唑类化合物及其应用
US10022357B2 (en) 2013-04-29 2018-07-17 The General Hospital Corporation Amyloid precursor protein MRNA blockers for treating Down syndrome and Alzheimer's disease
WO2016061190A1 (en) 2014-10-14 2016-04-21 The Board Of Trustees Of The Leland Stanford Junior University Method for treating neurodegenerative diseases
CN104873500A (zh) 2015-04-29 2015-09-02 中国人民解放军第四军医大学 化合物zln005的用途
EP3294715B1 (en) 2015-05-11 2020-05-06 Kancera AB Benzimidazole derivates useful as inhibitors of mammalian histone deacetylase activity
ES2830447T3 (es) * 2015-12-15 2021-06-03 Univ Leland Stanford Junior Método para la prevención y/o el tratamiento del deterioro cognitivo asociado al envejecimiento y la neuroinflamación
CN108602812B (zh) 2015-12-22 2021-11-02 坎塞拉有限公司 可用作哺乳动物组蛋白去乙酰化酶活性的抑制剂的双环异羟肟酸类化合物
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション 2−置換アミノ−ナフト[1,2−d]イミダゾール−5−オン化合物またはその製薬学上許容される塩
BR112021002165A2 (pt) 2018-08-06 2021-05-04 The Board Of Trustees Of The Leland Stanford Junior University composto, composição farmacêutica, e, métodos para tratar uma doença neurodegenerativa e deficiência cognitiva associada ao envelhecimento e neuroinflamação

Also Published As

Publication number Publication date
MX2021001456A (es) 2021-05-27
AU2019319745B2 (en) 2025-06-26
US11111217B2 (en) 2021-09-07
US20210300877A1 (en) 2021-09-30
IL307972A (en) 2023-12-01
JP7422737B2 (ja) 2024-01-26
CN119033775A (zh) 2024-11-29
CN112805000A (zh) 2021-05-14
IL280664A (en) 2021-03-25
US20210061769A1 (en) 2021-03-04
IL298535A (en) 2023-01-01
IL280664B2 (en) 2023-04-01
IL280664B (en) 2022-12-01
AU2019319745A1 (en) 2021-03-25
SG11202101285YA (en) 2021-03-30
JP2021534099A (ja) 2021-12-09
MX2023012694A (es) 2023-11-21
EP3833344A4 (en) 2022-07-06
US12195432B2 (en) 2025-01-14
US10851066B2 (en) 2020-12-01
US20200299244A1 (en) 2020-09-24
EP3833344A1 (en) 2021-06-16
KR20210068399A (ko) 2021-06-09
JP2024056694A (ja) 2024-04-23
BR112021002165A2 (pt) 2021-05-04
TWI904076B (zh) 2025-11-11
WO2020033359A1 (en) 2020-02-13
TW202019410A (zh) 2020-06-01
IL298535B2 (en) 2024-03-01
IL298535B1 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
AU2019319745B2 (en) 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases
AU2019373203B2 (en) Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha
RU2684641C1 (ru) Производные пиразолопиридина в качестве модуляторов активности tnf
JP5416696B2 (ja) オキサジアゾール誘導体およびそれらの代謝型グルタミン酸受容体増強剤としての使用
JP5140577B2 (ja) ヒドロキシステロイドデヒドロゲナーゼ阻害剤
JP2020509041A (ja) アミド類誘導体阻害剤及びその製造方法と使用
EP3986879B1 (en) Fused 1,2-thiazoles and 1,2-thiazines which act as nlrp3 modulators
TW201925173A (zh) 鹵代烯丙基胺類ssao/vap-1抑制劑及其用途
EP2262808A2 (en) Chemokine receptor modulators
JP7678595B2 (ja) ピロロ[2,3‐b]ピリジン‐3‐カルボキサミド組成物及び聴力損失を改善するための方法
JP2022521536A (ja) イミダゾピリジニル化合物及び神経変性障害の処置のためのその使用
JP2010523725A (ja) 皮膚疾患処置用ホスホジエステラーゼ阻害剤としてのトリアゾロピリジン
WO2009085256A1 (en) Anti-hiv compounds
JP2020503293A (ja) β−セクレターゼ阻害剤としてのオキサジン誘導体および使用方法
WO2006017409A2 (en) 1,3-disubstituted heteroaryl nmda/nr2b antagonists
SK285571B6 (sk) 8,8a-Dihydroindeno[1,2-d]tiazolové deriváty nesúce v polohe 2 substituent so sulfónamidovou štruktúrou, spôsob ich prípravy a farmaceutické prostriedky, ktoré ich obsahujú
KR20190086445A (ko) Dyrk1 억제제로서의 벤조사이아졸 유도체
JP2021524469A (ja) Nrf2アクチベーターとしてのインダン
TW202502756A (zh) 作為il17的調節劑的新穎化合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220408

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240704

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240905

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241217

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250115

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250115

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250709

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250804

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250804

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251110

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260703

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260723

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260723